149 related articles for article (PubMed ID: 35194718)
41. Nanoconfinement of a Pharmaceutical Cocrystal with Praziquantel in Mesoporous Silica: The Influence of the Solid Form on Dissolution Enhancement.
Salas-Zúñiga R; Mondragón-Vásquez K; Alcalá-Alcalá S; Lima E; Höpfl H; Herrera-Ruiz D; Morales-Rojas H
Mol Pharm; 2022 Feb; 19(2):414-431. PubMed ID: 34967632
[TBL] [Abstract][Full Text] [Related]
42. Variability in commercial carbamazepine samples--impact on drug release.
Flicker F; Eberle VA; Betz G
Int J Pharm; 2011 May; 410(1-2):99-106. PubMed ID: 21435386
[TBL] [Abstract][Full Text] [Related]
43. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method.
Sethia S; Squillante E
J Pharm Sci; 2002 Sep; 91(9):1948-57. PubMed ID: 12210042
[TBL] [Abstract][Full Text] [Related]
44. A novel strategy for pharmaceutical cocrystal generation without knowledge of stoichiometric ratio: myricetin cocrystals and a ternary phase diagram.
Hong C; Xie Y; Yao Y; Li G; Yuan X; Shen H
Pharm Res; 2015 Jan; 32(1):47-60. PubMed ID: 24939640
[TBL] [Abstract][Full Text] [Related]
45. Novel Aceclofenac Cocrystals with l-Cystine: Virtual Coformer Screening, Mechanochemical Synthesis, and Physicochemical Investigations.
Kumar S; Gupta A; Prasad R; Singh S
Curr Drug Deliv; 2021; 18(1):88-100. PubMed ID: 32807053
[TBL] [Abstract][Full Text] [Related]
46. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph.
Rodríguez-Hornedo N; Murphy D
J Pharm Sci; 2004 Feb; 93(2):449-60. PubMed ID: 14705201
[TBL] [Abstract][Full Text] [Related]
47. Improved in vitro and in vivo performance of carbamazepine enabled by using a succinic acid cocrystal in a stable suspension formulation.
Ullah M; Shah MR; Bin Asad MHH; Hasan SMF; Hussain I
Pak J Pharm Sci; 2017 Nov; 30(6):2139-2145. PubMed ID: 29175782
[TBL] [Abstract][Full Text] [Related]
48. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds.
Shiraki K; Takata N; Takano R; Hayashi Y; Terada K
Pharm Res; 2008 Nov; 25(11):2581-92. PubMed ID: 18651208
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms by which moisture generates cocrystals.
Jayasankar A; Good DJ; Rodríguez-Hornedo N
Mol Pharm; 2007; 4(3):360-72. PubMed ID: 17488034
[TBL] [Abstract][Full Text] [Related]
50. Virtual Screening, Structural Analysis, and Formation Thermodynamics of Carbamazepine Cocrystals.
Surov AO; Ramazanova AG; Voronin AP; Drozd KV; Churakov AV; Perlovich GL
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986697
[TBL] [Abstract][Full Text] [Related]
51. Adsorption onto Mesoporous Silica Using Supercritical Fluid Technology Improves Dissolution Rate of Carbamazepine-a Poorly Soluble Compound.
Gandhi AV; Thipsay P; Kirthivasan B; Squillante E
AAPS PharmSciTech; 2017 Nov; 18(8):3140-3150. PubMed ID: 28534299
[TBL] [Abstract][Full Text] [Related]
52. Novel cocrystals of itraconazole: Insights from phase diagrams, formation thermodynamics and solubility.
Vasilev NA; Surov AO; Voronin AP; Drozd KV; Perlovich GL
Int J Pharm; 2021 Apr; 599():120441. PubMed ID: 33675927
[TBL] [Abstract][Full Text] [Related]
53. Investigation of intrinsic dissolution behavior of different carbamazepine samples.
Sehić S; Betz G; Hadzidedić S; El-Arini SK; Leuenberger H
Int J Pharm; 2010 Feb; 386(1-2):77-90. PubMed ID: 19900519
[TBL] [Abstract][Full Text] [Related]
54. Small-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration.
Box KJ; Comer J; Taylor R; Karki S; Ruiz R; Price R; Fotaki N
AAPS PharmSciTech; 2016 Apr; 17(2):245-51. PubMed ID: 26208438
[TBL] [Abstract][Full Text] [Related]
55. Stabilization mechanism of amorphous carbamazepine by transglycosylated rutin, a non-polymeric amorphous additive with a high glass transition temperature.
Aoki C; Ma X; Higashi K; Ishizuka Y; Ueda K; Kadota K; Fukuzawa K; Tozuka Y; Kawakami K; Yonemochi E; Moribe K
Int J Pharm; 2021 May; 600():120491. PubMed ID: 33744450
[TBL] [Abstract][Full Text] [Related]
56. Novel Salt-Cocrystals of Berberine Hydrochloride with Aliphatic Dicarboxylic Acids: Odd-Even Alternation in Physicochemical Properties.
Wang L; Liu S; Chen JM; Wang YX; Sun CC
Mol Pharm; 2021 Apr; 18(4):1758-1767. PubMed ID: 33656348
[TBL] [Abstract][Full Text] [Related]
57. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
[TBL] [Abstract][Full Text] [Related]
58. Cocrystals of acyclovir with promising physicochemical properties.
Sarkar A; Rohani S
J Pharm Sci; 2015 Jan; 104(1):98-105. PubMed ID: 25407552
[TBL] [Abstract][Full Text] [Related]
59. Pharmaceutical salts/cocrystals of enoxacin with dicarboxylic acids: Enhancing in vitro antibacterial activity of enoxacin by improving the solubility and permeability.
Liu L; Zou D; Zhang Y; Zhang Q; Feng Y; Guo Y; Liu Y; Zhang X; Cheng G; Wang C; Zhang Y; Zhang L; Wu L; Chang L; Su X; Duan Y; Zhang Y; Liu M
Eur J Pharm Biopharm; 2020 Sep; 154():62-73. PubMed ID: 32645384
[TBL] [Abstract][Full Text] [Related]
60. Cocrystals Mitigate Negative Effects of High pH on Solubility and Dissolution of a Basic Drug.
Chen YM; Rodríguez-Hornedo N
Cryst Growth Des; 2018 Mar; 18(3):1358-1366. PubMed ID: 30505243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
